Who we are?

john devrill exhalation technology
Executive Chairman of the Board

John Deverill

Linkedin Envelope
About

John is the Executive Chairman of the Board at Exhalation Technology, bringing over 25 years of experience in MedTech and healthcare. A former army officer and qualified engineer, he has held senior roles at GE Healthcare, boutique consultancies, large corporates, and within the NHS.

He has led strategic partnerships across Europe, the Middle East, and Africa, and advised on system transformation and market access. At Exhalation Technology, John guides the company’s strategic direction and growth while also serving as chair and non-executive director within the NHS.

Advisor to the Board

Dr. Graham Clarke

Linkedin
About

Graham is a proven R&D leader with 20+ years of experience de-risking pipelines, accelerating development, and driving asset differentiation across pharma, biotech, and med tech. At AstraZeneca, he built the company’s early precision medicine infrastructure—advancing biomarker-driven trials, patient stratification, and strategic CRO alliances across Immunology and Respiratory portfolios.

Previously VP at hVIVO and Head of Respiratory early clinical development at IQVIA, he launched innovative Phase 1/2 services and led validation of novel biomarker platforms, including breath and airway sampling diagnostics.

He holds a PhD from King’s College London, where he is also Visiting Professor, and lectures widely on precision medicine and R&D strategy.

Board Member

Claus Holmelund

Envelope
About

Profile coming soon. More information about Claus will be added shortly.

Financial Advisor

Michael Shaw

Envelope
About

Profile coming soon. More information about Michael will be added shortly.

Exhalation Technologies Limited acquired the business and assets formerly operated by Exhalation Technology Limited on 30 September 2026. The business, technology and Inflammacheck programme are now operated by Exhalation Technologies Limited, company number 17347428.